How to fix fragmentation without pretending it doesn’t exist
There’s an assumption in clinical trials that doesn’t get challenged nearly enough: If each system is good… then more systems must be better. More specialised. More powerful. More “best-of-breed”. But spend a day at a clinical trial site, and that logic starts to unravel.
There’s a quiet lie circulating in clinical trials. It’s dressed up as sophistication. It sounds like maturity. It often appears in RFPs.
How to fix fragmentation without pretending it doesn’t exist
There’s an assumption in clinical trials that doesn’t get challenged nearly enough: If each system is good… then more systems must be better. More specialised. More powerful. More “best-of-breed”. But spend a day at a clinical trial site, and that logic starts to unravel.
There’s a quiet lie circulating in clinical trials. It’s dressed up as sophistication. It sounds like maturity. It often appears in RFPs.
How to fix fragmentation without pretending it doesn’t exist
There’s an assumption in clinical trials that doesn’t get challenged nearly enough: If each system is good… then more systems must be better. More specialised. More powerful. More “best-of-breed”. But spend a day at a clinical trial site, and that logic starts to unravel.
There’s a quiet lie circulating in clinical trials. It’s dressed up as sophistication. It sounds like maturity. It often appears in RFPs.
How to fix fragmentation without pretending it doesn’t exist
There’s an assumption in clinical trials that doesn’t get challenged nearly enough: If each system is good… then more systems must be better. More specialised. More powerful. More “best-of-breed”. But spend a day at a clinical trial site, and that logic starts to unravel.
There’s a quiet lie circulating in clinical trials. It’s dressed up as sophistication. It sounds like maturity. It often appears in RFPs.
Today’s highlight
Clinical trial start-up — the phase encompassing vendor onboarding, system build and configuration, site activation and training — persistently consumes time, introduces friction and contributes to costly delays in getting first patient in. For decades this has been driven by an industry-wide reliance on narrative, unstructured protocols and disconnected operational hand-offs.
Why clinical trial technology buyers and sellers need to step up in 2026 In case you’ve been living under a rock - or buried under a pile of protocols - there’s a meme doing the rounds on LinkedIn and X that goes something like this: “I just had a deeply personal life experience… and here’s what it taught me about B2B sales.”
Why clinical trial technology buyers and sellers need to step up in 2026 In case you’ve been living under a rock - or buried under a pile of protocols - there’s a meme doing the rounds on LinkedIn and X that goes something like this: “I just had a deeply personal life experience… and here’s what it taught me about B2B sales.”
If you want to understand where clinical trials are heading, don’t start with conferences or consensus papers. Start with the one thing that never lies: capital allocation.
If you want to understand where clinical trials are heading, don’t start with conferences or consensus papers. Start with the one thing that never lies: capital allocation.
If clinical trials were a game of Where’s Waldo?, eligibility criteria would be Waldo’s sunglasses: tiny, easy to miss, and capable of derailing your search if you overlook them. For decades, finding the right participants i.e. the people who actually meet the labyrinthine inclusion and exclusion rules, has been a slow, painstaking quest. And while sites and sponsors pour hours of human effort into sifting through charts, an elephant has quietly stepped into the room wearing a speed-boosted jersey: artificial intelligence.
If clinical trials were a game of Where’s Waldo?, eligibility criteria would be Waldo’s sunglasses: tiny, easy to miss, and capable of derailing your search if you overlook them. For decades, finding the right participants i.e. the people who actually meet the labyrinthine inclusion and exclusion rules, has been a slow, painstaking quest. And while sites and sponsors pour hours of human effort into sifting through charts, an elephant has quietly stepped into the room wearing a speed-boosted jersey: artificial intelligence.
Latest posts
How to fix fragmentation without pretending it doesn’t exist
There’s an assumption in clinical trials that doesn’t get challenged nearly enough: If each system is good… then more systems must be better. More specialised. More powerful. More “best-of-breed”. But spend a day at a clinical trial site, and that logic starts to unravel.
There’s a quiet lie circulating in clinical trials. It’s dressed up as sophistication. It sounds like maturity. It often appears in RFPs.
Clinical trial start-up — the phase encompassing vendor onboarding, system build and configuration, site activation and training — persistently consumes time, introduces friction and contributes to costly delays in getting first patient in. For decades this has been driven by an industry-wide reliance on narrative, unstructured protocols and disconnected operational hand-offs.
Why clinical trial technology buyers and sellers need to step up in 2026 In case you’ve been living under a rock - or buried under a pile of protocols - there’s a meme doing the rounds on LinkedIn and X that goes something like this: “I just had a deeply personal life experience… and here’s what it taught me about B2B sales.”
If you want to understand where clinical trials are heading, don’t start with conferences or consensus papers. Start with the one thing that never lies: capital allocation.
How to fix fragmentation without pretending it doesn’t exist
There’s an assumption in clinical trials that doesn’t get challenged nearly enough: If each system is good… then more systems must be better. More specialised. More powerful. More “best-of-breed”. But spend a day at a clinical trial site, and that logic starts to unravel.
There’s a quiet lie circulating in clinical trials. It’s dressed up as sophistication. It sounds like maturity. It often appears in RFPs.
Clinical trial start-up — the phase encompassing vendor onboarding, system build and configuration, site activation and training — persistently consumes time, introduces friction and contributes to costly delays in getting first patient in. For decades this has been driven by an industry-wide reliance on narrative, unstructured protocols and disconnected operational hand-offs.
